NFKB1 and diabetic cardiomyopathy: In conclusion, triptolide treatment significantly attenuates cardiac inflammation and fibrosis through suppressing the activity and the expression of NF-κB, resulting in improved LV function in experimental diabetic cardiomyopathy.